日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors

PARP抑制剂CEP-9722单药治疗或与替莫唑胺联合治疗实体瘤患者的I期剂量递增研究

Plummer, Ruth; Stephens, Peter; Aissat-Daudigny, Louiza; Cambois, Anne; Moachon, Gilbert; Brown, Peter D; Campone, Mario

Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral Therapy

接受高效抗逆转录病毒疗法的人类免疫缺陷病毒感染患者体内替诺福韦的群体药代动力学

Jullien, Vincent; Tréluyer, Jean-Marc; Rey, Elisabeth; Jaffray, Patrick; Krivine, Anne; Moachon, Laurence; Louet, Agnès Lillo-Le; Lescoat, Anne; Dupin, Nicolas; Salmon, Dominique; Pons, Gérard; Urien, Saïk